CoChat

SGLT2 Inhibitors and Mechanisms of Hypertension

Briasoulis, Alexandros, Al Dhaybi, Omar, Bakris, George L. · 2018 · Current Cardiology Reports

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Purpose of review We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Recent findings Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone. Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression. However, concerns about volume depletion and acute kidney injury have been raised. SGLT2 inhibitors are viable second-line glucose-lowering agents for people with type 2 diabetes with high cardiovascular risk.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11886-018-0943-5

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Cited by

See all 99

Metadata

Authors
Briasoulis, A., Al Dhaybi, O., & Bakris, G. L.
Affiliations
University of Chicago (US)
Corresponding author
Bakris, George L.
Venue
Current Cardiology Reports
Published
2018-01
Volume
20
Issue
1
Pages
1-1
ISSN
  • 1523-3782 (ISSN-L)
  • 1534-3170
OpenAlex
W2785530117
Cited by
94
References
56
Citations by year
2026: 3 · 2025: 9 · 2024: 11 · 2023: 9 · 2022: 11 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 5
FWCI
1.96
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Cardiology Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
SGLT2 inhibitors, hypertension, type 2 diabetes, blood pressure reduction, sodium excretion, sympathetic tone, acute kidney injury, hypovolemia, cardiovascular risk, kidney disease progression, canagliflozin, dapagliflozin, empagliflozin, urinary glucose excretion, body weight
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT2 Inhibitors and Mechanisms of Hypertension. https://app.cochat.ai/papers/10.1007/s11886-018-0943-5
The paper
Briasoulis, A., Al Dhaybi, O., & Bakris, G. L. (2018). SGLT2 Inhibitors and Mechanisms of Hypertension. Current Cardiology Reports. https://doi.org/10.1007/s11886-018-0943-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.